Valiant(SZ:002643) Bank of China Securities·2025-09-11 05:15Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 13.29 and an industry rating of "Outperform" [1]. Core Views - The company's pharmaceutical business has shown improvement, with a year-on-year revenue decrease of 4.42% to RMB 1.87 billion in the first half of 2025, but a net profit increase of 1.35% to RMB 218 million. The second quarter saw a revenue of RMB 1.01 billion, a slight year-on-year decrease of 0.95%, but a quarter-on-quarter increase of 17.12% [3][7]. - The report highlights the company's diverse new material layouts and the successful recovery of its pharmaceutical business, leading to an upward revision of profit forecasts [4][7]. Financial Summary - For the first half of 2025, the company reported total revenue of RMB 1.87 billion, with a net profit of RMB 218 million, reflecting a 1.35% increase year-on-year. The second quarter's net profit was RMB 138 million, up 18.25% year-on-year [8][9]. - The company expects EPS for 2025-2027 to be RMB 0.44, RMB 0.54, and RMB 0.63, with corresponding P/E ratios of 30.4x, 24.7x, and 21.2x respectively [4][6]. - The company is actively expanding its production capacity in various new materials, including semiconductor manufacturing materials and thermoplastic polyimide materials, which are expected to contribute to long-term growth [7][8].